Vos Erik M, Greebe Paut, Visser-Meily J M Anne, Rinkel Gabriel J E, Vergouwen Mervyn D I
Brain Center Rudolf Magnus, Department of Neurology and Neurosurgery (EMV, PG, GJER, MDIV) and Center of Excellence for Rehabilitation Medicine (JMAV-M), University Medical Center Utrecht, Utrecht, The Netherlands.
Brain Center Rudolf Magnus, Department of Neurology and Neurosurgery (EMV, PG, GJER, MDIV) and Center of Excellence for Rehabilitation Medicine (JMAV-M), University Medical Center Utrecht, Utrecht, The Netherlands.
J Neurol Sci. 2017 Jan 15;372:184-186. doi: 10.1016/j.jns.2016.11.062. Epub 2016 Nov 24.
Sensorineural hearing impairment is a key symptom in patients with superficial siderosis of the central nervous system, a disease caused by chronic or intermittent haemorrhage into the subarachnoid space. We investigated the prevalence and risk factors of subjective hearing impairment after SAH.
We systematically interviewed all SAH patients admitted between June 2011 and December 2014, who were able to visit the SAH outpatient clinic six to eight weeks after hospital discharge. We calculated the proportion of patients with subjective hearing impairment noticed after SAH onset, and adjusted risk ratios (aRR) with 95% confidence intervals (CI) for potential risk factors with Poisson regression.
We included 277 patients. Subjective hearing impairment was reported by 54/277 (19%) patients (aneurysmal SAH: 42/212 [20%;95%CI:15-26%]; perimesencephalic haemorrhage 8/36 [22%;95%CI:12-38%], non-aneurysmal non-perimesencephalic SAH: 4/29 [14%;95%CI:6-31%]). Hearing impairment was associated with a poor clinical condition on admission (defined as PAASH score 4-5) (aRR3.00;95%CI:1.43-6.28), aneurysm rupture at the middle cerebral artery (aRR2.72;95%CI:1.38-5.39), and moderate/severe disability 3months after ictus (aRR2.25;95%CI:1.28-3.97), but not with large amounts of extravasated blood (highest vs. lowest tertile of Hijdra score) (aRR0.77;95%CI:0.33-1.81) or endovascular treatment (aRR1.19;95%CI:0.61-2.33).
Subjective hearing impairment occurs in 1 of every 5 SAH patients. It is related to the clinical condition on admission, aneurysm rupture at the middle cerebral artery, and functional outcome, but not to the amount of subarachnoid blood or the method of aneurysm occlusion. Audiometric tests, auditory cognitive assessments, and follow-up studies are needed to determine the cause and prognosis of hearing impairment after SAH.
感音神经性听力障碍是中枢神经系统表面铁沉积症患者的关键症状,该疾病由蛛网膜下腔慢性或间歇性出血引起。我们调查了蛛网膜下腔出血(SAH)后主观听力障碍的患病率及危险因素。
我们对2011年6月至2014年12月期间收治的所有SAH患者进行了系统访谈,这些患者在出院后六至八周能够前往SAH门诊就诊。我们计算了SAH发病后出现主观听力障碍的患者比例,并通过泊松回归分析对潜在危险因素计算调整风险比(aRR)及95%置信区间(CI)。
我们纳入了277例患者。54/277(19%)例患者报告有主观听力障碍(动脉瘤性SAH:42/212 [20%;95%CI:15 - 26%];中脑周围出血8/36 [22%;95%CI:12 - 38%],非动脉瘤性非中脑周围SAH:4/29 [14%;95%CI:6 - 31%])。听力障碍与入院时临床状况较差(定义为PAASH评分4 - 5)(aRR 3.00;95%CI:1.43 - 6.28)、大脑中动脉动脉瘤破裂(aRR 2.72;95%CI:1.38 - 5.39)以及发病后3个月中度/重度残疾(aRR 2.25;95%CI:1.28 - 3.97)相关,但与大量外渗血液(Hijdra评分最高三分位数与最低三分位数相比)(aRR 0.77;95%CI:0.33 - 1.81)或血管内治疗(aRR 1.19;95%CI:0.61 - 2.33)无关。
每5例SAH患者中就有1例出现主观听力障碍。它与入院时的临床状况、大脑中动脉动脉瘤破裂及功能转归有关,但与蛛网膜下腔出血量或动脉瘤闭塞方法无关。需要进行听力测试、听觉认知评估及随访研究以确定SAH后听力障碍的原因及预后。